Premium
Phase II trial of cisplatin (CPDD) in previously treated patients with advanced soft tissue sarcoma
Author(s) -
Brenner Joseph,
Magill Gordon B.,
Sordillo Peter P.,
Cheng Edgar W.,
Yagoda Allan
Publication year - 1982
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19821115)50:10<2031::aid-cncr2820501010>3.0.co;2-z
Subject(s) - medicine , nausea , soft tissue sarcoma , vomiting , soft tissue , toxicity , nephrotoxicity , ototoxicity , phases of clinical research , surgery , chemotherapy , cisplatin
Thirty‐six previously treated adult patients with advanced soft tissue sarcomas received CPDD 120 mg/m 2 with mannitol diuresis. There were only two (6%) partial responses and five (15%) minor responses in 34 evaluable patients. Toxicity included nausea and vomiting, myelosuppression, mild ototoxicity and mild to moderate, transient nephrotoxicity. CPDD has minimal antitumor activity in previously treated patients with soft tissue sarcomas.